International Symposium on Trends in Radiopharmaceuticals (ISTR-2019)

Session

S.1

28 Oct 2019, 11:00

M1 (M Building)

231. M. Venkatesh: Production of reactor based radioisotopes: An international portfolio (IS)

Meera Venkatesh

28/10/2019, 11:00

232. R. Mikolajczak: Production and supply of medical radioisotopes: A Polish experience (IS)

28/10/2019, 11:25

233. Selective separation of no carrier added 47Sc from reactor irradiated Ca using zirconium vanadate gel for nuclear medical applications (9)

Mohamed Gizawy (Lecturer at Radioisotopes Production Facility (RPF), Egyptian Second Research Reactor (ETRR-2), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt)

28/10/2019, 11:45

23. Synthesis and neutron activation of Lu2O3 nanoparticles functionalized with target specific peptides

Ms Guillermina Ferro-Flores

28/10/2019, 12:00

Background
The preparation of 177Lu-peptides for targeted radionuclide therapy requires the use of lutetium-177 from medium to high specific activity (from 400 to 3000 GBq/mg), which cannot be obtained in low flux research nuclear reactors [1,2]. However, the synthesis of 176Lu in the form of injectable nanoparticles functionalized with target-specific peptides, would allow to irradiate in the...

8. Towards a robust supply chain for medical radioisotopes

Mr Titus Tielens (PALLAS)

28/10/2019, 12:15

Oral

Background / objective:
Demand for nuclear medicines for diagnostic, therapeutic and theranostic use is growing fast, driven by the development of highly effective novel drugs against cancer and life-threatening diseases. Whereas molybdenum-99 is the most commonly used isotope for diagnostic SPECT scans, it is expected that lutetium-177 will be the main workhorse in the coming decades for...

220. Test Abstract

Vojna Ngjeqari

Production of PET- and SPECT-based diagnostic, therapeutic and theranostic medical radioisotopes-1

Poster

nano technology